Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
296 results about "Immunotherapeutic agent" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Synergistic Anti-tumor efficacy using alloantigen combination immunotherapy
InactiveUS20130071403A1Increased activationOrganic active ingredientsAntibody ingredientsImmunotherapeutic agentIrritation
The present disclosure provides combinations of immunotherapeutics and methods for treating medical conditions that are characterized by the lack of an effective immune response, for example as would result following a down-regulation of MHC class I, such as in cancer. The immunotherapeutic compositions of the invention, which can be used to treat the medical conditions, include one or more immunostimulatory antibodies or molecules having specificity for CTLA-4, PD-1, PD-L1, PD-L2, CD40, OX40, CD137, GITR, ILT2, or ILT3, or ligands for these molecules (e.g., an isolated fully-human monoclonal antibody) in association with one or more alloantigens, such as, vector(s) capable of expressing protein(s) or peptide(s) that stimulate T-cell immunity against tissues or cells, formulated in a pharmaceutically acceptable carrier. The proteins or peptides may comprise class I major histocompatibility complex (MHC) antigens, β2-microglobulins, or cytokines. The MHC antigen may be foreign to the subject. The MHC antigen may be HLA-B7.
Owner:VICAL INC
Targeting of Antigen Presenting Cells with Immunonanotherapeutics
ActiveUS20100129392A1Improve responsePowder deliverySnake antigen ingredientsNanocarriersImmunotherapeutic agent
The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides nanocarriers capable of stimulating an immune response in T cells and / or in B cells. The invention provides nanocarriers that comprise an immunofeature surface. The nanocarriers are capable of targeting antigen presenting cells when administered to a subject. The invention provides pharmaceutical compositions comprising inventive nanocarriers. The present invention provides methods of designing, manufacturing, and using inventive nanocarriers and pharmaceutical compositions thereof.
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE +2
Inhibition of placenta growth factor (PLGF) mediated metastasis and/or angiogenesis
InactiveUS20070087001A1Inhibit or eliminate tumor metastasisPrevent tumors from metastasizingSenses disorderPeptide/protein ingredientsAbnormal tissue growthLymphatic Spread
The present invention concerns methods and compositions for inhibiting angiogenesis and / or tumor growth, survival and / or metastasis. In particular embodiments, the methods and compositions may concern ligands against placenta growth factor (PlGF), such as BP-1, BP-2, BP-3 or BP-4. Some methods may comprise administering one or more PlGF ligands, alone or in combination with one or more other agents, such as chemotherapeutic agents, other anti-angiogenic agents, immunotherapeutic agents or radioimmunotherapeutic agents to a subject. The PlGF ligands are effective to inhibit angiogenesis, tumor cell motility, tumor metastasis, tumor growth and / or tumor survival. In certain embodiments, PlGF ligands may be administered to subjects to ameliorate other angiogenesis related conditions, such as macular degeneration. In some embodiments, PlGF expression levels may be determined by any known method to select those patients most likely to respond to PlGF targeted therapies.
Owner:CENT FOR MOLECULAR BIOLOGY & MEDICINE +1
Nanoparticles for immunotherapy
Nanoparticles that activate complement in the absence of biological molecules are described. The nanoparticles are shown to specifically target antigen presenting cells in specifically in lymph nodes, without the use of a biological molecule for targeting. These particles are useful vehicles for delivering immunotherapeutics. Surface chemistries and chemical formulations for the nanoparticles are described.
Owner:ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL)
Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
ActiveCN101213297AMicrobiological testing/measurementImmunoglobulins against cell receptors/antigens/surface-determinantsImmunotherapeutic agentProgrammed death
The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.
Owner:ONO PHARMA CO LTD +1
Mutant interleukin-2 polypeptides
ActiveUS20120244112A1Eliminates and decrease and delayEliminates and decrease and and and effectPeptide/protein ingredientsAntibody mimetics/scaffoldsImmunotherapeutic agentReceptor
The present invention generally relates to mutant interleukin-2 polypeptides that exhibit reduced affinity to the α-subunit of the IL-2 receptor, for use as immunotherapeutic agents. In addition, the invention relates to immunoconjugates comprising said mutant IL-2 polypeptides, polynucleotide molecules encoding the mutant IL-2 polypeptides or immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant IL-2 polypeptides or immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.
Owner:ROCHE GLYCART AG
Mutant interleukin-2 polypeptides
ActiveUS9266938B2Eliminates and decrease and delayEliminates and decrease and and and effectPeptide/protein ingredientsAntibody mimetics/scaffoldsImmunotherapeutic agentNucleotide
The present invention generally relates to mutant interleukin-2 polypeptides that exhibit reduced affinity to the α-subunit of the IL-2 receptor, for use as immunotherapeutic agents. In addition, the invention relates to immunoconjugates comprising said mutant IL-2 polypeptides, polynucleotide molecules encoding the mutant IL-2 polypeptides or immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant IL-2 polypeptides or immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.
Owner:ROCHE GLYCART AG
Inhibition of placenta growth factor (PLGF) mediated metastasis and/or angiogenesis
InactiveUS7642239B2Inhibit or eliminate tumor metastasisPrevent tumors from metastasizingSenses disorderPeptide/protein ingredientsLymphatic SpreadImmunotherapeutic agent
Owner:CENT FOR MOLECULAR BIOLOGY & MEDICINE +1
Stress proteins and uses therefor
InactiveUS6338952B1Preventing and reducing adverse effectEnhance immune responseVirusesAntibody mimetics/scaffoldsAntigenImmunotherapeutic agent
The present invention relates to stress proteins and methods of modulating an individual's immune response. In particular, it relates to the use of such stress proteins in immune therapy and prophylaxis, which results in an induction or enhancement of an individual's immune response and as an immunotherapeutic agent which results in a decrease of an individual's immune response to his or her own cells. The present invention also relates to compositions comprising a stress protein joined to another component, such as a fusion protein in which a stress protein is fused to an antigen. Further, the present invention relates to a method of generating antibodies to a substance using a conjugate comprised of a stress protein joined to the substance.
Owner:WHITEHEAD INST FOR BIOMEDICAL RES INC
Novel proteosome-liposaccharide vaccine adjuvant
InactiveUS20030044425A1Increase secretionUniform processSsRNA viruses negative-senseBiocideImmunotherapeutic agentCytokine
An adjuvant complex composed of bacterial outer membrane protein proteosomes complexed to bacterial liposaccharide is prepared to contain the component parts under a variety of conditions. The complex can be formulated with antigenic material to form immunogenic compositions, vaccines and immunotherapeutics. An induced immune response includes protective antibodies and / or type 1 cytokines is shown for a variety of protocols.
Owner:ID BIOMEDICAL CORP LAVAL
Mutant interleukin-2 polypeptides
ActiveUS20160208017A1Eliminates and decrease and delayEliminates and decrease and and and effectPeptide/protein ingredientsAntibody mimetics/scaffoldsImmunotherapeutic agentNucleotide
The present invention generally relates to mutant interleukin-2 polypeptides that exhibit reduced affinity to the α-subunit of the IL-2 receptor, for use as immunotherapeutic agents. In addition, the invention relates to immunoconjugates comprising said mutant IL-2 polypeptides, polynucleotide molecules encoding the mutant IL-2 polypeptides or immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant IL-2 polypeptides or immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.
Owner:ROCHE GLYCART AG
Vaccines and immunotherapeutics using codon optimized IL-15 and methods for using the same
InactiveUS8178660B2Sugar derivativesGenetic material ingredientsImmunotherapeutic agentRecombinant vaccines
Nucleic acid molecules that encode IL-15 or fragments thereof, which express protein at a higher level than nucleic acid molecules with native coding sequences for IL-15 are disclosed. Nucleic acid molecules with additional modifications such as the absence of coding sequences for IL-15 signal sequences and / or the absence of IL-15 untranslated sequences and / or inclusion of non-IL-15 signal sequences are also disclosed. Vectors, including plasmids and viral vectors, comprising such nucleic acid molecules; and to host cells comprising such nucleic acid molecules are disclosed as well as methods of using such nucleic acid molecules alone or in combination with nucleic acid sequences encoding immunogens which are part of the nucleic acid molecules and / or part of a different nucleic acid molecule. Recombinant vaccines and live attenuated pathogens encoding fusion proteins, and methods of using the same, are disclosed.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA
Sheddase inhibitors combined with cd30-binding immunotherapeutics for the treatment of cd30 positive diseases
The present invention is directed to pharmaceutical methods for the treatment of CD30 positive diseases, such as Hodgkin's disease, by administration of a combination of at least one sheddase inhibitor and at least one anti-CD30 immunotherapeutic.
Owner:INCYTE
Linked immunotherapeutic agonists that costimulate multiple pathways
InactiveUS20150307620A1Immunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsImmunotherapeutic agentMonoclonal antibody
Described herein are modified immunotherapeutic agents including a first monoclonal antibody covalently linked to a second monoclonal antibody generating a single new immunotherapeutic agent. The first and second monoclonal antibodies stimulate different anti-tumor pathways. Advantageously, the modified single immunotherapeutic agent is capable of activating both anti-tumor pathways. Also included herein are methods of treating cancer with the modified immunotherapeutic agents.
Owner:UNIV OF CONNECTICUT
Combinations of tumor-associated antigens in diagnostics for various types of cancers
Disclosed herein are methods for matching a cancer condition with an appropriate immunotherapeutic agent and / or regimen. Also disclosed are methods for confirming diagnosis of a particular type of cancer. Embodiments of the invention disclosed herein are directed to the use of effective combinations of TuAAs to optimize the match between a patient's cancer condition and available immunotherapies.
Owner:MANNKIND CORP
Focused radiation for augmenting immune-based therapies against neoplasms
ActiveUS9132281B2Inhibiting, reducing, or counteracting an immunosuppressive effect of a tumor in a subjectEliminate the effects ofEnergy modified materialsImmunoglobulins against cytokines/lymphokines/interferonsAdjuvantImmunotherapeutic agent
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
Purification of heat shock/stress protein cell surface receptors and their use as immunotherapeutic agents
InactiveUS6797480B1Improve isolationBiocidePeptide/protein ingredientsAntigenImmunotherapeutic agent
The present invention relates to receptors for heat shock proteins (HSPs), such as gp96, Hsp70 and Hsp90. The heat shock receptor is associated with the cell membranes of a subset of antigen presenting cells, such as macrophages and dendritic cells. The present invention relates to the use of the heat shock protein receptor positive cells, heat shock protein receptor protein, and heat shock protein receptor genes in methods for screening a molecule for the ability to modulate heat shock protein levels or activities.
Owner:CONNECTICUT HEALTH CENT UNIV OF
Nanoparticles for immunotherapy
Nanoparticles that activate complement in the absence of biological molecules are described. The nanoparticles are shown to specifically target antigen presenting cells in specifically in lymph nodes, without the use of a biological molecule for targeting. These particles are useful vehicles for delivering immunotherapeutics. Surface chemistries and chemical formulations for the nanoparticles are described.
Owner:ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL)
Contextual fear conditioning for predicting immunotherapeutic efficacy
InactiveUS20060153772A1Increase awarenessImprovement in the context-dependent memoryCompounds screening/testingContextual fearClinical psychology
Owner:JANSSEN ALZHEIMER IMMUNOTHERAPY +1
Use of biomolecular targets in the treatment and visualization of brain tumors
Owner:ER SQUIBB & SONS INC
Synergistic Anti-tumor efficacy using alloantigen combination immunotherapy
InactiveUS20130280265A1Increased activationOrganic active ingredientsAntibody ingredientsImmunotherapeutic agentEfficacy
The present disclosure provides combinations of immunotherapeutics and methods for treating medical conditions that are characterized by the lack of an effective immune response, for example as would result following a down-regulation of MHC class I, such as in cancer. The immunotherapeutic compositions of the invention, which can be used to treat the medical conditions, include one or more immunostimulatory antibodies or molecules having specificity for CTLA-4, PD-1, PD-L1, PD-L2, CD40, OX40, CD137, GITR, ILT2, or ILT3, or ligands for these molecules (e.g., an isolated fully-human monoclonal antibody) in association with one or more alloantigens, such as, vector(s) capable of expressing protein(s) or peptide(s) that stimulate T-cell immunity against tissues or cells, formulated in a pharmaceutically acceptable carrier. The proteins or peptides may comprise class I major histocompatibility complex (MHC) antigens, β2-microglobulins, or cytokines. The MHC antigen may be foreign to the subject. The MHC antigen may be HLA-B7.
Owner:VICAL INC
Vaccines and immunotherapeutics using il-28 and compositions and methods of using the same
ActiveUS20110104105A1SsRNA viruses negative-senseAntibacterial agentsImmunotherapeutic agentRecombinant vaccines
Compositions, recombinant vaccines and live attenuated pathogens comprising one or more isolated nucleic acid molecules that encode an immunogen in combination with an isolated nucleic acid molecule that encodes IL-28 or a functional fragment thereof are disclosed. Methods of inducing an immune response in an individual against an immunogen, using such compositions are disclosed.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA
Lif/lifr antagonist in oncology and nonmalignant diseases
InactiveUS20200087340A1Reduce the amount requiredOrganic active ingredientsAndrostane derivativesDiseaseImmunotherapeutic agent
Described herein are methods of using compounds that inhibit leukemia inhibitory factor (LIF) and / or block of the leukemia inhibitory factor receptor for treatment of liver fibrosis, proliferation of spinal tumors, and in combination therapy with an immunotherapeutic agent.
Owner:EVESTRA
Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
ActiveCN103059138ARadioactive preparation carriersImmunoglobulins against cell receptors/antigens/surface-determinantsAntiendomysial antibodiesInfectious Disorder
The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.
Owner:ONO PHARMA CO LTD +1
Cancer treatments
The invention relates to a product comprised of specific combinations of cell lines intended for use as an allogeneic immunotherapy agent for the treatment of prostate cancer in humans. The heterogeneity of the immunotherapeutic matches the heterogeneity of the antigenic profile in the target prostate cancer and immunises the recipients with many of the potential TAA and TSA which are expressed at various stages of the disease. The invention discloses a vaccine comprising a combination of three different cell lines prepared from primary or metastatic prostate cancer biopsy material. The cell lines are lethally irradiated utilising gamma irradiation at 50-300 Gy to ensure that they are replication incompetent.
Owner:ONYVAX
Cancer therapy
A method is provided for treating mammals, including humans, with advanced or large-tumour burdens. The method involves administering an immunotherapeautic agent in conjunction with a tumour growth restricting agent, in amounts effective to eradicate any advanced or large tumours present. In preferred embodiments, the immunotherapeautic agent comprises a T-cell co-stimulatory cell adhesion molecule (CAM) or a mammalian expression vector containing DNA which encodes a T-cell co-stimulatory CAM, such as B7.1, and the tumour growth restricting agent is flavone acetic acid, 5,6-dimenthyl-xanthenone-4-acetic acid, or an agent which disrupts the expression or activity of hypoxia-inducible factor-1 (HIF-1).
Owner:CANCER RES TECH LTD +1
Vaccines, immunotherapeutics and methods for using the same
InactiveUS8119395B1Enhance and modulate immune responseUseful for immunotherapyAntibacterial agentsVirusesDiseaseAntigen
Improved vaccines which include a nucleotide sequence that encodes immunomodulating protein operably linked to regulatory elements are disclosed. The improved vaccines include DNA vaccines, recombinant vaccines for delivering foreign antigen and live attenuated vaccines. Methods of immunizing individuals are disclosed. Compositions for and methods of treating individuals with autoimmune diseases are disclosed.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA
Antigen delivery vectors and constructs
ActiveUS20060013820A1Improving immunogenicityOptimise steric presentation of antigenAntibacterial agentsOrganic active ingredientsVirologyAntigen delivery
The present invention relates to fluorocarbon vectors for the delivery of antigens to immunoresponsive target cells. It further relates to fluorocarbon vector-antigen constructs and the use of such vectors associated with antigens as vaccines and immunotherapeutics in animals.
Owner:ALTIMMUNE UK LTD
Nanoparticles for photodynamic therapy, x-ray induced photodynamic therapy, radiotherapy, chemotherapy, immunotherapy, and any combination thereof
ActiveCN107001031AExhibit nanorod morphologyPowder deliveryPhotodynamic therapyCo administrationImmunotherapeutic agent
Metal-organic frameworks (MOFs) comprising photosensitizers are described. The MOFs can also include moieties capable of absorbing X- rays and / or scintillation. Optionally, the photosensitizer or a derivative thereof can form a bridging ligand of the MOF. Further optionally, the MOF can comprise inorganic nanoparticles in the cavities or channels of the MOF or can be used in combination with an inorganic nanoparticle. Also described are methods of using MOFs and / or inorganic nanoparticles in photodynamic therapy or in X-ray induced photodynamic therapy, either with or without the co-administration of one or more immunotherapeutic agent and / or one or more chemotherapeutic agent.
Owner:UNIVERSITY OF CHICAGO
Antigen delivery vectors and constructs
ActiveUS7687455B2Improving immunogenicityOptimise steric presentation of antigenAntibacterial agentsOrganic active ingredientsAntigen deliveryImmunotherapeutic agent
The present invention relates to fluorocarbon vectors for the delivery of antigens to immunoresponsive target cells. It further relates to fluorocarbon vector-antigen constructs and the use of such vectors associated with antigens as vaccines and immunotherapeutics in animals.
Owner:ALTIMMUNE UK LTD
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com